Candidemia: Evolution of Drug Resistance and Novel Therapeutic Approaches

References

• Koehler P, Stecher M, Cornely OA, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect. 2019;25(10):1200–1212. doi:10.1016/j.cmi.2019.04.02431039444
   PubMed Web of Science ®Google Scholar
• Prigitano A, Cavanna C, Passera M. Evolution of fungemia in an Italian region. J Mycol Med. 2020;30(1):100906. doi:10.1016/j.mycmed.2019.10090631708424
   PubMed Web of Science ®Google Scholar
• Pappas P, Lionakis M, Arendrup M, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018;4(1):18026. doi:10.1038/nrdp.2018.2629749387
   PubMed Web of Science ®Google Scholar
• Wan Ismail WNA, Jasmi N, Khan TM, Hong YH, Neoh CF. The economic burden of candidemia and invasive candidiasis: a systematic review. Value Health Reg Issues. 2020;21:53–58. doi:10.1016/j.vhri.2019.07.00231648147
   PubMedGoogle Scholar
• Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the SENTRY antifungal surveillance program: results for Candida species from 1997–2016. Open Forum Infect Dis. 2019;6(Suppl 1):S79–S94. doi:10.1093/ofid/ofy35830895218
   PubMed Web of Science ®Google Scholar
• Vincent BM, Lancaster AK, Scherz-Shouval R, Whitesell L, Lindquist S. Fitness trade-offs restrict the evolution of resistance to amphotericin B. PLoS Biol. 2013;11(10):e1001692. doi:10.1371/journal.pbio.100169224204207
   PubMed Web of Science ®Google Scholar
• Lockhart SR. Current epidemiology of Candida infection. Clin Microbiol Newsletter. 2014;36(17):131–136. doi:10.1016/j.clinmicnews.2014.08.001
   Google Scholar
• Castanheira M, Deshpande LM, Messer SA, Rhomberg PR, Pfaller MA. Analysis of global antifungal surveillance results reveals predominance of Erg11 Y132F alteration among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific isolate dissemination. Int J Antimicrob Agents. 2020;55:105799. doi:10.1016/j.ijantimicag.2019.09.00331520783
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol. 2012;50(4):1199–1203. doi:10.1128/JCM.06112-1122278842
   PubMed Web of Science ®Google Scholar
• Tóth R, Nosek J, Mora-Montes HM. Candida parapsilosis: from genes to the bedside. Clin Microbiol Rev. 2019;32:e00111–18. doi:10.1128/CMR.00111-1830814115
   PubMed Web of Science ®Google Scholar
• Chiotos K, Vendetti N, Zaoutis TE, et al. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12). Antimicrob Chemother. 2016;71(12):3536–3539. doi:10.1093/jac/dkw305
   Web of Science ®Google Scholar
• Arendrup MC, Friberg N, Mares M, Kahlmeter G, Meletiadis J, Guinea J. How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). Clin Microbiol Infect. 2020;26(11):1464–1472. doi:10.1016/j.cmi.2020.06.00732562861
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Caggiano G, Falconi Di Francesco L, Montagna MT, Barbuti S, Scalise G. Outbreak of fungemia due to Candida parapsilosis in a pediatric oncology unit. Diagn Microbiol Infect Dis. 2004;49(4):269‐271. doi:10.1016/j.diagmicrobio.2004.03.011
   Web of Science ®Google Scholar
• Ngamchokwathana C, Chongtrakool P, Waesamaae A, Chayakulkeeree M. Risk factors and outcomes of non-albicans Candida bloodstream infection in patients with candidemia at Siriraj Hospital-Thailand’s largest national tertiary referral hospital. J Fungi. 2021;7:269. doi:10.3390/jof7040269
   Web of Science ®Google Scholar
• Jensen RH, Arendrup MC. Candida palmioleophila: characterization of a previously overlooked pathogen and its unique susceptibility profile in comparison with five related species. J Clin Microbiol. 2011;49(2):549–556. doi:10.1128/JCM.02071-1021147953
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017;13(5):e1006290. doi:10.1371/journal.ppat.100629028542486
   PubMed Web of Science ®Google Scholar
• Rutala WA, Kanamori H, Gergen MF, Sickbert-Bennett EE, Weber DJ. Susceptibility of Candida auris and Candida albicans to 21 germicides used in healthcare facilities. Infect Control Hosp Epidemiol. 2019;40:380–382. doi:10.1017/ice.2019.130767810
   PubMed Web of Science ®Google Scholar
• Osei Sekyere J. Candida auris: a systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen. Microbiol Open. 2018;7(4):e00578. doi:10.1002/mbo3.578
   Web of Science ®Google Scholar
• Iguchi S, Itakura Y, Yoshida A, et al. Candida auris: a pathogen difficult to identify, treat, and eradicate and its characteristics in Japanese strains. J Infect Chemother. 2019;25(10):743–749. doi:10.1016/j.jiac.2019.05.03431257156
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Prakash A, Sharma C, et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018;73(4):891–899. doi:10.1093/jac/dkx48029325167
   PubMed Web of Science ®Google Scholar
• Szekely A, Borman AM, Johnson EM. Candida auris isolates of the Southern Asian and South African lineages exhibit different phenotypic and antifungal susceptibility profiles in vitro. J Clin Microbiol. 2019;57:e02055–18. doi:10.1128/JCM.02055-1830867237
   PubMed Web of Science ®Google Scholar
• Sanguinetti M, Posteraro B, Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses. 2015;58(Suppl. 2):2–13. doi:10.1111/myc.12330
   PubMed Web of Science ®Google Scholar
• Perlin DS, Rautemaa-Richardson R, Alastruey-Izquierdo A. The global problem of antifungal resistance: prevalence, mechanisms, and management. Lancet Infect Dis. 2017;17:e383–392. doi:10.1016/S1473-3099(17)30316-X28774698
   PubMed Web of Science ®Google Scholar
• Robbins N, Caplan T, Cowen LE. Molecular evolution of antifungal drug resistance. Annu Rev Microbiol. 2017;71:753–775. doi:10.1146/annurev-micro-030117-02034528886681
   PubMed Web of Science ®Google Scholar
• Revie NM, Iyer KR, Robbins N, Cowen LE. Antifungal drug resistance: evolution, mechanisms and impact. Curr Opin Microbiol. 2018;45:70–76. doi:10.1016/j.mib.2018.02.00529547801
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Patterson TF. Multidrug-Resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis. 2017;216(S3):S445–451. doi:10.1093/infdis/jix13128911043
   PubMed Web of Science ®Google Scholar
• Costa C, Ponte A, Pais P, et al. New mechanisms of flucytosine resistance in C. glabrata unveiled by a chemogenomics analysis in S. cerevisiae. PLoS One. 2015;10:e0135110. doi:10.1371/journal.pone.013511026267134
   PubMed Web of Science ®Google Scholar
• Cavalheiro M, Teixeira MC. Candida Biofilms: threats, challenges, and promising strategies. Front Med. 2018;5:28. doi:10.3389/fmed.2018.00028
   PubMed Web of Science ®Google Scholar
• Katragkou A, Kruhlak MJ, Simitsopoulou M, et al. Interactions between human phagocytes and Candida albicans biofilms alone and in combination with antifungal agents. J Infect Dis. 2010;201(12):1941–1949. doi:10.1086/65278320415537
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Miyagawa S, Takeda O, et al. Real-time microscopic observation of Candida biofilm development and effects due to micafungin and fluconazole. Antimicrob Agents Chemother. 2013;57(5):2226–2230. doi:10.1128/AAC.02290-1223459484
   PubMed Web of Science ®Google Scholar
• Simitsopoulou M, Peshkova P, Tasina E, et al. Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates. Antimicrob Agents Chemother. 2013;57(6):2562–2570. doi:10.1128/AAC.02541-1223529739
   PubMed Web of Science ®Google Scholar
• Toulet D, Debarre C, Imbert C. Could liposomal amphotericin B (L-AMB) lock solutions be useful to inhibit Candida spp. biofilms on silicone biomaterials? J Antimicrob Chemother. 2012;67:430–432. doi:10.1093/jac/dkr47322081268
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):409–417. doi:10.1093/cid/civ119426810419
   PubMed Web of Science ®Google Scholar
• Pfaller M, Neofytos D, Diekema D, et al. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance) registry, 2004–2008. Diagn Microbiol Infect Dis. 2012;74:323–331. doi:10.1016/j.diagmicrobio.2012.10.00323102556
   PubMed Web of Science ®Google Scholar
• Andes DR, Safdar N, Baddley JW, et al. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials. Clin Infect Dis. 2012;54:1110–1122. doi:10.1093/cid/cis02122412055
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Akova M, Herbrecht R. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;7:53–67. doi:10.1111/1469-0691.12041
   Web of Science ®Google Scholar
• Kollef M, Micek S, Hampton N, Doherty JA, Kumar A. Septic shock attributed to Candida infection: importance of empiric therapy and source control. Clin Infect Dis. 2012;54:1739–1746. doi:10.1093/cid/cis30522423135
   PubMed Web of Science ®Google Scholar
• Ostrosky-Zeichner L, Kullberg BJ, Bow EJ, et al. Early treatment of candidemia in adults: a review. Med Mycol. 2011;49:113–120. doi:10.3109/13693786.2010.51230020818922
   PubMed Web of Science ®Google Scholar
• Fernandez-Cruz A, Menarguez MC, Pedromingo M, et al. Candida endocarditis: yield of echocardiogram in patients with candidemia. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy: Boston, MA; 2010.K–2172.
   Google Scholar
• Oude Lashof AM, Sobel JD, Ruhnke M, et al. Safety and tolerability of voriconazole in patients with baseline renal insufficiency and candidemia. Antimicrob Agents Chemother. 2012;56:3133–3137. doi:10.1128/AAC.05841-1122450974
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bassetti M, Calandra T, et al. ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect. 2012;7:19–37. doi:10.1111/1469-0691.12039
   Web of Science ®Google Scholar
• Antinori S, Milazzo L, Sollima S, Galli M, Corbellino M. Candidemia and invasive candidiasis in adults: a narrative review. Eur J Intern Med. 2016;34:21–28. doi:10.1016/j.ejim.2016.06.02927394927
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242–1250. doi:10.1086/49692716206097
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356:2472–2482. doi:10.1056/NEJMoa06690617568028
   PubMed Web of Science ®Google Scholar
• Reboli AC, Shorr AF, Rotstein C, et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infect Dis. 2011;11:261. doi:10.1186/1471-2334-11-26121961941
   PubMed Web of Science ®Google Scholar
• Kett DH, Azoulay E, Echeverria PM, Vincent JL. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med. 2011;39:665–670. doi:10.1097/CCM.0b013e318206c1ca21169817
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008–2009. Antimicrob Agents Chemother. 2011;55:561–566. doi:10.1128/AAC.01079-1021115790
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Moet GJ, Messer SA, Jones RN, Castanheira M. Geographic variations in species distribution and echinocandin and azole antifungal resistance rates among Candida bloodstream infection isolates: report from the SENTRY Antimicrobial Surveillance Program (2008 to 2009). J Clin Microbiol. 2011;49:396–399. doi:10.1128/JCM.01398-1021068282
   PubMed Web of Science ®Google Scholar
• Fernandez-Ruiz M, Aguado JM, Almirante B, et al. Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. Clin Infect Dis. 2014;58:1413–1421. doi:10.1093/cid/ciu15824642553
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(347):2020–2029. doi:10.1056/NEJMoa02158512490683
   PubMed Web of Science ®Google Scholar
• Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal Amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369:1519–1527. doi:10.1016/S0140-6736(07)60605-917482982
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Sanz MA, Tramarin A, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis. 2006;43(4):e29–38. doi:10.1086/50596916838223
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331(20):1325–1330. doi:10.1056/NEJM1994111733120017935701
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Vartivarian SE, Abi-Said D, et al. Fluconazole versus amphotericin B in the treatment of hematogenous candidiasis: a matched cohort study. Am J Med. 1996;101(2):170–176. doi:10.1016/S0002-9343(96)80072-68757357
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet. 2005;366(9495):1435–1442. doi:10.1016/S0140-6736(05)67490-916243088
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883–893. doi:10.1086/52098017806055
   PubMed Web of Science ®Google Scholar
• Seiler GT, Ostrosky-Zeichner L. Investigational agents for the treatment of resistant yeasts and molds. Curr Fungal Infect Rep. 2021;1–12. doi:10.1007/s12281-021-00419-5
   Web of Science ®Google Scholar
• Gamal A, Chu S, McCormick TS, Borroto-Esoda K, Angulo D, Ghannoum MA. Ibrexafungerp, a novel oral triterpenoid antifungal in development: overview of antifungal activity against Candida glabrata. Front Cell Infect Microbiol. 2021;11:642358. doi:10.3389/fcimb.2021.64235833791244
   PubMed Web of Science ®Google Scholar
• Schwebke JR, Sobel R, Gersten JK, et al. Ibrexafungerp versus placebo for vulvovaginal candidiasis treatment: a Phase 3, randomized, controlled superiority trial (VANISH 303). Clin Infect Dis;2021. ciab750. doi:10.1093/cid/ciab75034467969
   PubMed Web of Science ®Google Scholar
• Mesquida A, Vicente T, Reigadas E, et al. In vitro activity of ibrexafungerp and comparators against Candida albicans genotypes from vaginal samples and blood cultures. Clin Microbiol Infect. 2021;27(6):915.e5–915.e8. doi:10.1016/j.cmi.2021.02.006
   Web of Science ®Google Scholar
• Arendrup MC, Jørgensen KM, Hare RK, Chowdhary A. In Vitro activity of ibrexafungerp (SCY-078) against Candida auris isolates as determined by EUCAST Methodology and Comparison with Activity against C. albicans and C. glabrata and with the activities of six comparator agents. Antimicrob Agents Chemother. 2020;64(3):e02136–19. doi:10.1128/AAC.02136-1931844005
   PubMed Web of Science ®Google Scholar
• Zhao Y, Perlin DS. Review of the novel echinocandin antifungal rezafungin: animal studies and clinical data. J Fungi. 2020;6(4):192. doi:10.3390/jof6040192
   Web of Science ®Google Scholar
• Pfaller MA, Carvalhaes C, Messer SA, Rhomberg PR, Castanheira M. Activity of a long-acting echinocandin, rezafungin, and comparator antifungal agents tested against contemporary invasive fungal isolates (SENTRY Program, 2016 to 2018). Antimicrob Agents Chemother. 2020;64(4):e00099–20. doi:10.1128/AAC.00099-2032015043
   PubMed Web of Science ®Google Scholar
• Helleberg M, Jørgensen KM, Hare RK, Datcu R, Chowdhary A, Arendrup MC. Rezafungin in Vitro activity against contemporary Nordic clinical Candida isolates and Candida auris determined by the EUCAST Reference Method. Antimicrob Agents Chemother. 2020;64(4):e02438–19. doi:10.1128/AAC.02438-1932015032
   PubMed Web of Science ®Google Scholar
• Thompson GR, Soriano A, Skoutelis A, et al. Rezafungin versus Caspofungin in a phase 2, randomized, double-blind study for the treatment of candidemia and invasive candidiasis- the STRIVE trial. Clin Infect Dis;2020. ciaa1380. doi:10.1093/cid/ciaa1380
   Web of Science ®Google Scholar
• Brand SR, Degenhardt TP, Person K, et al. A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of orally administered VT-1161 in the treatment of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol. 2018;218(6):624.e1–624.e9. doi:10.1016/j.ajog.2018.03.001
   Web of Science ®Google Scholar
• Brand SR, Sobel JD, Nyirjesy P, Ghannoum MA, Schotzinger RJ, Degenhardt TP. Randomized phase 2 Study of VT-1161 for the treatment of acute vulvovaginal candidiasis. Clin Infect Dis. 2020;1:ciaa1204.
   Google Scholar
• Nishimoto AT, Wiederhold NP, Flowers SA, et al. In vitro activities of the novel investigational tetrazoles VT-1161 and VT-1598 compared to the triazole antifungals against azole-resistant strains and clinical isolates of Candida albicans. Antimicrob Agents Chemother. 2019;63(6):e00341–19.
   Google Scholar
• Schell WA, Jones AM, Garvey EP, Hoekstra WJ, Schotzinger RJ, Alexander BD. Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C. krusei isolates clinically resistant to azole and echinocandin antifungal compounds. Antimicrob Agents Chemother. 2017;61(3):e01817–16. doi:10.1128/AAC.01817-1627956419
   PubMed Web of Science ®Google Scholar
• Shaw KJ, Ibrahim AS. Fosmanogepix: a review of the first-in-class broad spectrum agent for the treatment of invasive fungal infections. J Fungi. 2020;6(4):239. doi:10.3390/jof6040239
   Web of Science ®Google Scholar
• Pfaller MA, Huband MD, Flamm RK, Bien PA, Castanheira M. Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019). J Glob Antimicrob Resist. 2021;26:117–127. doi:10.1016/j.jgar.2021.04.01234051400
   PubMed Web of Science ®Google Scholar
• Arendrup MC, Jørgensen KM. Manogepix (APX001A) displays potent in vitro activity against human pathogenic yeast, but with an unexpected correlation to fluconazole MICs. Antimicrob Agents Chemother. 2020;64(7):e00429–20. doi:10.1128/AAC.00429-2032366708
   PubMed Web of Science ®Google Scholar